Your browser doesn't support javascript.

Biblioteca Virtual em Saúde


Home > Pesquisa > ()
Imprimir Exportar

Formato de exportação:


Adicionar mais destinatários
| |

KSR2 mutations are associated with obesity, insulin resistance, and impaired cellular fuel oxidation.

Pearce, Laura R; Atanassova, Neli; Banton, Matthew C; Bottomley, Bill; van der Klaauw, Agatha A; Revelli, Jean-Pierre; Hendricks, Audrey; Keogh, Julia M; Henning, Elana; Doree, Deon; Jeter-Jones, Sabrina; Garg, Sumedha; Bochukova, Elena G; Bounds, Rebecca; Ashford, Sofie; Gayton, Emma; Hindmarsh, Peter C; Shield, Julian P H; Crowne, Elizabeth; Barford, David; Wareham, Nick J; O'Rahilly, Stephen; Murphy, Michael P; Powell, David R; Barroso, Ines; Farooqi, I Sadaf.
Cell; 155(4): 765-77, 2013 Nov 07.
Artigo em Inglês | MEDLINE | ID: mdl-24209692
Kinase suppressor of Ras 2 (KSR2) is an intracellular scaffolding protein involved in multiple signaling pathways. Targeted deletion of Ksr2 leads to obesity in mice, suggesting a role in energy homeostasis. We explored the role of KSR2 in humans by sequencing 2,101 individuals with severe early-onset obesity and 1,536 controls. We identified multiple rare variants in KSR2 that disrupt signaling through the Raf-MEKERK pathway and impair cellular fatty acid oxidation and glucose oxidation in transfected cells; effects that can be ameliorated by the commonly prescribed antidiabetic drug, metformin. Mutation carriers exhibit hyperphagia in childhood, low heart rate, reduced basal metabolic rate and severe insulin resistance. These data establish KSR2 as an important regulator of energy intake, energy expenditure, and substrate utilization in humans. Modulation of KSR2-mediated effects may represent a novel therapeutic strategy for obesity and type 2 diabetes.
Selo DaSilva